Guggenheim Cuts PT On Perrigo (PRGO) By 30%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to Guggenheim Cuts PT On Perrigo (PRGO) By 30%
April 27, 2016 12:13 AM EDT
By Sarah N. Lynch and Bill Berkrot
WASHINGTON/NEW YORK (Reuters) - Activist investor William Ackman promised U.S. lawmakers on Wednesday that he will urge the board of Valeant Pharmaceuticals (NYSE: VRX) to reduce the high prices of four life-saving drugs that are now at the heart of two congressional probes.
Speaking before the Senate Special Committee on Aging, Ackman revealed that Valeant's board will hold a conference call on Thursday to discuss the costs of heart medications Isuprel and Nitropress, as well as Cuprimine and Syprine, two drugs... More
April 26, 2016 8:28 AM EDT
RBC Capital analyst, Randall Stanicky, cut his target on Perrigo Co. (NYSE: PRGO) to $109 from $140 as the estimate cuts overshadow even the loss of a CEO. No change to Sector Perform rating.
The departure of CEO Joe Papa to join VRX wasn't... More
April 26, 2016 8:26 AM EDT
Perrigo (NYSE: PRGO) declared a quarterly dividend of $0.145 per share, or $0.58 annualized.
The dividend will be payable on June 14, 2016, to stockholders of record on May 27, 2016, with an ex-dividend date of May 25, 2016.
The annual yield on the dividend is 0.6 percent.
For a... More
